ITEM VIEW

Treatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen

dc.contributor.authorFentiman I.S.
dc.contributor.authorVan Zijl J.
dc.contributor.authorKarydas I.
dc.contributor.authorChaudary M.A.
dc.contributor.authorMargreiter R.
dc.contributor.authorLegrand C.
dc.contributor.authorTherasse P.
dc.date.accessioned2011-05-15T16:16:18Z
dc.date.available2011-05-15T16:16:18Z
dc.date.issued2003
dc.identifier.citationEuropean Journal of Cancer
dc.identifier.citation39
dc.identifier.citation3
dc.identifier.issn09598049
dc.identifier.other10.1016/S0959-8049(02)00672-X
dc.identifier.urihttp://hdl.handle.net/10019.1/13720
dc.description.abstractWe have examined the outcome of older patients with operable breast cancer treated in a randomised trial by either standard surgery or less extensive surgery and tamoxifen. There were 236 participants aged ≥70 years, randomised to either modified radical mastectomy MRM (n=120) or wide local excision (WLE) and tamoxifen (T) 20 mg daily (n=116). Survival curves were estimated using the Kaplan-Meier method and multivariate analyses were performed using Cox's proportional hazards model. Endpoints were survival and time to first relapse or progression, loco-regional progression, time to distant progression and progression-free survival. No significant difference was seen in terms of progression-free survival, but there were significantly more loco-regional relapses in the WLE+T group. In contrast, there were more distant metastases in the MRM group, but with a similar overall survival in both groups. The results of this trial give cautious support for the use of WLE+T for selected older women. © 2003 Elsevier Science Ltd. All rights reserved.
dc.subjecttamoxifen
dc.subjectage
dc.subjectaged
dc.subjectanalytic method
dc.subjectarticle
dc.subjectbreast carcinoma
dc.subjectcancer growth
dc.subjectcancer recurrence
dc.subjectcancer research
dc.subjectcancer surgery
dc.subjectcancer survival
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthazard assessment
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmastectomy
dc.subjectmultivariate analysis
dc.subjectpriority journal
dc.subjectsurgical technique
dc.subjecttreatment outcome
dc.subjectAge Factors
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Agents, Hormonal
dc.subjectBreast Neoplasms
dc.subjectCombined Modality Therapy
dc.subjectDisease Progression
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectHumans
dc.subjectMastectomy, Radical
dc.subjectMultivariate Analysis
dc.subjectNeoplasm Metastasis
dc.subjectNeoplasm Recurrence, Local
dc.subjectRisk Factors
dc.subjectSalvage Therapy
dc.subjectTamoxifen
dc.titleTreatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW